Pam3CSK4 (TFA)

• UNSPSC Description:

  Pam3CSK4 TFA is a toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2[1].

• Target Antigen:

  Toll-like Receptor (TLR)

• Type:

  Peptides

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pam3csk4-tfa.html

• Purity:

  99.66

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)|H2O : 16.67 mg/mL (ultrasonic)

• Smiles:

  OC(C(F)(F)F)=O.CCCCCCCCCCCCCCCC(OCC(OC(CCCCCCCCCCCCCCC)=O)CSC[C@H](NC(CCCCCCCCCCCCCCC)=O)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O

• Molecular Weight:

  1852.30

• References & Citations:

  [1]Irvine KL, et al. The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6. Vet Res. 2013 Jul 4;44:50.|[2]Du X, et al. Systemic stimulation of TLR2 impairs neonatal mouse brain development. PLoS One. 2011 May 6;6(5):e19583.|[3]Chen Y, et al. TLR2 agonist Pam3CSK4 enhances the antibacterial functions of GM-CSF induced neutrophils to methicillin-resistant Staphylococcus aureus. Microb Pathog. 2019 May;130:204-212.Chin Herb Med. 2024 Jul.|Int Immunopharmacol. December 2022, 109312.|J Pharm Anal. 2024 Jul 23.|Sci China Life Sci. 2024 Aug 22.|Sci Rep. 2022 Oct 12;12(1):17058.|Antiviral Res. 2022 May 21;203:105346.|Biochem Biophys Res Commun. 2024 Feb 15, 149661.|Emerg Microbes Infect. 2023 Oct 30:105244.|Int Immunopharmacol. 2022 Feb 15;106:108613.|Mol Immunol. 2021 Feb;130:85-95.|Sci Rep. 2023 Nov 9;13(1):19440.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  112208-01-2